EntroGen, Inc. specializes in molecular diagnostics for oncology and hematology, offering a comprehensive range of solutions that encompass hardware, reagents, and software. Their product portfolio includes real-time PCR and next-generation sequencing (NGS) assays tailored for various cancers, such as colorectal, breast, lung, melanoma, glioblastoma, and thyroid cancers. The company emphasizes the importance of accurate and scalable diagnostic solutions, which begin with automated nucleic acid extraction and extend to genomic interpretation through proprietary software designed to support key clinical decisions. This end-to-end approach aims to enhance the development of targeted therapies in oncology.

The company's offerings include a variety of mutation analysis kits and panels that facilitate the detection of specific genetic alterations associated with different cancers. For instance, EntroGen provides targeted hotspot panels for NGS platforms and multiple real-time PCR kits for detecting mutations in genes such as KRAS, PIK3CA, and EGFR. Their products are designed to support companion diagnostics and aid in the identification of actionable mutations, thereby contributing to personalized treatment strategies for patients. Overall, EntroGen's technologies are focused on advancing precision medicine in oncology through innovative diagnostic solutions.

United States

We are a biotechnology company offering end-to-end solutions in molecular diagnostic for oncology and hematology by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with its proprietary software embedded throughout entire workflow, EntroGen solutions are designed to be accurate, economic and scalable. EntroGen sells CRCdx®, a U.S. FDA-approved product.

EntroGen

Company Details